USNA — USANA Health Sciences Income Statement
0.000.00%
- $311.92m
- $220.71m
- $925.26m
Annual income statement for USANA Health Sciences, fiscal year end - January 3rd, USD millions except per share, conversion factor applied.
2022 December 31st | 2022 January 1st | 2023 December 30th | 2024 December 28th | 2026 January 3rd | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 999 | 1,186 | 921 | 855 | 925 |
| Cost of Revenue | |||||
| Gross Profit | 805 | 969 | 744 | 693 | 724 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 891 | 1,016 | 828 | 788 | 888 |
| Operating Profit | 108 | 170 | 93.1 | 66.3 | 37.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 109 | 171 | 102 | 76.4 | 41.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 69.3 | 117 | 63.8 | 42.1 | 11.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 69.3 | 117 | 63.8 | 42 | 10.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 69.3 | 117 | 63.8 | 42 | 10.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.59 | 5.73 | 3.3 | 2.19 | 1.05 |